Purpose It remains unclear whether changes in arterial wall inflammation are associated with subsequent changes in the rate of structural progression of atherosclerosis. Methods In this sub-study of the dal-PLAQUE clinical trial, multi-modal imaging was performed using 18-fludeoxyglucose (FDG) positron emission tomography (PET, at 0 and 6 months) and magnetic resonance imaging (MRI, at 0 and 24 months). The primary objective was to determine whether increasing FDG uptake at 6 months predicted atherosclerosis progression on MRI at 2 years. Arterial inflammation was measured by the carotid FDG target-to-background ratio (TBR), and atherosclerotic plaque progression was defined as the percentage change in carotid mean wall area (MWA) and mean wall thickness (MWT) on MRI between baseline and 24 months. Results A total of 42 participants were included in this sub-study. The mean age of the population was 62.5 years, and 12 (28.6 %) were women. In participants with (vs. without) any increase in arterial inflammation over 6 months, the long-term changes in both MWT (% change MWT: 17.49 % vs. 1.74 %, p = 0.038) and MWA (% change MWA: 25.50 % vs. 3.59 %, p = 0.027) were significantly greater. Results remained significant after adjusting for clinical and biochemical covariates. Individuals with no increase in arterial inflammation over 6 months had no significant structural progression of atherosclerosis over 24 months as measured by MWT (p = 0.616) or MWA (p = 0.373). Conclusions Short-term changes in arterial inflammation are associated with long-term structural atherosclerosis progression. These data support the concept that therapies that reduce arterial inflammation may attenuate or halt progression of atherosclerosis. 
Introduction
Atherosclerosis and its major clinical consequences, myocardial infarction and stroke, are leading causes of mortality and morbidity worldwide. Inflammation plays a crucial role in the development and progression of atherosclerosis, and can be non-invasively measured using 18-fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/ CT) [1, 2] . FDG is a glucose analog that is retained within cells at a rate proportional to glucose-dependent metabolism, and compared to other vascular cells, FDG uptake is avid in immune cells. In the vascular wall, this correlates strongly with atherosclerotic plaque burden and macrophage infiltration [3] . Rapid changes in FDG arterial uptake have been observed in humans in response to therapeutic interventions [4, 5] . However, there are limited data regarding how these short-term changes in inflammatory activity in an arterial wall relate to subsequent atherosclerosis progression.
The dal-PLAQUE study was a phase 2b double-blind, randomized, placebo-controlled trial examining the effects of the cholesteryl ester transfer protein (CETP) modulator dalcetrapib on structural and inflammatory characteristics of arterial wall atherosclerosis by PET/CT over a 6-month period, and/or by magnetic resonance imaging [MRI] imaging over 24 months [6] . With both serial imaging of carotid inflammation and structural evaluation of the arteries, dal-PLAQUE provides a unique opportunity to test the hypothesis that changes in arterial inflammation over time affect plaque progression. Prior analysis of dal-PLAQUE identified a significant association between changes in carotid arterial inflammation over 6 months and enlargement of the total vessel area at 24 months. However, total vessel area (TVA) includes both the arterial wall and lumen. Hence, TVA is a poor measure of atherosclerosis, since TVA could theoretically change due to changes in the lumen in the absence of changes in arterial wall parameters. Indeed, there are limited data examining the relationship between changes in arterial inflammation and atherosclerotic disease progression in humans. Accordingly, using measures that focused on the arterial wall (e.g. carotid arterial wall thickness and area measured by MRI), we examined whether short-term changes in arterial inflammation (measured by FDG-PET) predicted long-term changes in atherosclerosis progression.
Methods

Study design
This was a prospective sub-study of participants enrolled in the dal-PLAQUE clinical trial. The design of dal-PLAQUE has been described in detail in previous publications [6] . Briefly, dal-PLAQUE enrolled 130 participants from 11 centers in the United States and Canada. Participants were randomized (1:1) to receive either dalcetrapib 600 mg/day or placebo over a 24-month period. Participants could undergo 18-FDG-PET/CT to evaluate inflammation in the carotid arteries at 3 and 6 months, and/or black-blood MRI to assess anatomic indices of carotid plaque burden at 6, 12 and 24 months (undergoing all imaging time points was not required) [7] . This analysis included 42 participants from dal-PLAQUE who had serial FDG-PET/CT exams at baseline and 6 months and serial MRI exams at baseline and 2 years. The study was approved by each participating center's institutional review committee, and all subjects provided informed consent.
Imaging by PET/CT
Imaging protocols for FDG-PET/CT have been described in detail in previous publications. FDG-PET/CT imaging of the carotid arteries was performed using previously validated reproducible imaging methods [7] . Maximum standard uptake values (SUV) of FDG were measured, in axial orientation, along each carotid artery from 1 cm above to 2 cm below the bifurcation, by manually drawing circular regions of interest that encompassed the vessel wall at 3-5-mm increments. Target-to-background ratios (TBR) were calculated for each segment by dividing each SUV value by the background venous FDG activity measured in the internal jugular veins (see Fig. 1a ). The TBR of the most diseased segment (MDS) was calculated as a mean of the three contiguous segments centered at the vessel segment with the highest maximum TBR, and was used as the primary measure of FDG uptake for this study.
Imaging by MRI
MRI imaging of the common carotid arteries was performed using previously validated methods, which included proton density-weighted, T1-weighted and T2-weighted dark-blood turbo spin echo sequences to image the vessel walls, with additional phase contrast and time-of-flight sequences for better localization of carotid bifurcations [8] . External and internal walls of the carotid arteries were manually traced in crosssectional images spanning a 4-cm inferior section of the common carotids starting at the carotid bifurcation. For each crosssectional slice, the average wall thickness was calculated as the average of eight measurements, and the mean wall thickness MWT of each vessel calculated as the average of each slice. The carotid MWT, used as the primary analysis, was the average of the MWT for each vessel. The vessel wall area was calculated for each slice by subtracting the internal wall of the carotid artery from the internal wall. The mean wall area (MWA) of each artery was calculated as the average area of all slices, and the carotid MWA, used in the primary analysis, was the average of the MWA for each vessel (see Fig. 1b ).
Statistical analysis
For the primary analyses, we dichotomized participants into two groups, with either (1) an observed increase in carotid arterial inflammation (i.e. increase in TBR of the MDS) between baseline and 6 months, or (2) no increase in carotid arterial inflammation. Percentage changes in mean wall thickness (MWT) and mean wall area (MWA) of the carotid arteries were calculated by MRI between baseline and 24 months as the primary outcomes of interest.
The primary analysis assessed whether increased FDG activity at 6 months was associated with a significant difference in percentage change in MWT by MRI at 24 months using linear regression. Further multivariable linear regression analyses were performed to assess whether these differences remained significant after adjusting for (1) demographic variables and (2) selected baseline clinical, biochemical or imaging variables. Potential covariates were selected based on their established relationship with atherosclerosis development in prior literature, and included demographic variables (e.g. age, sex), cardiovascular risk factors, history of coronary artery disease, and biochemical markers of inflammation (e.g. Creactive protein [CRP] , interleukin-6 [IL-6]) and plasminogen activator inhibitor-1 [PAI-1] activity). Of these inflammatory biomarkers, PAI-1 activity was shown to predict changes in MWA on MRI in a prior dal-PLAQUE analysis [9] . Covariates significantly associated with MWT at 24 months on univariate analysis (at a threshold p value of 0.05) were carried forward in the multivariable analysis. Similar analyses were performed using the outcome of percentage change in MWA measured by MRI at 24 months. Sensitivity analyses were also performed using absolute changes in MWA and MWT.
Several exploratory analyses were also performed. To account for changes in the PET signal that could be attributable to differences in arterial wall area, we further adjusted for mean wall area at 6 months in our multivariable analysis. We also examined whether increased FDG activity remained a significant predictor of plaque progression by MRI after adjusting for biochemical markers of inflammatory activity, measured by C-reactive protein between baseline and 12 months. Also, in a subset of participants with FDG-PET imaging at 3 months, we examined whether arterial inflammation was associated with atherosclerotic progression by MRI at 2 years, and the correlation between the percentage change in SUV activity from baseline to 3 and 6 months. The association between changes in arterial inflammation and atherosclerosis progression, both measured between baseline and 6 months, was also examined. The association between baseline arterial inflammation and change in atherosclerosis were obtained at baseline and 6 months. Regions of interest were manually drawn over each cross section of the carotid artery (center) to calculate the standard uptake values (SUV) of FDG for each section of the carotid artery from 1 cm above to 2 cm below the bifurcation at 3-5-mm increments. The target-to-background ratios (TBR) were calculated for each segment by dividing each SUV value by the background venous FDG activity measured in the internal jugular veins. The TBR of the most diseased segment (MDS) was calculated as a mean of the three contiguous segments centered at the vessel segment with the highest maximum TBR (right). b MRI images were obtained for both carotid arteries at baseline and 24 months (left). To capture the vessel wall, two regions of interest were manually drawn to encompass the outer wall of the artery and its inner lumen in each cross-sectional image across the length of each carotid artery in order to calculate MWA and MWT (right). For each cross section, MWA was calculated by subtracting the total luminal area from the total vessel area (depicted in gray), while the MWT was calculated as the average thickness across eight measurements from the outer and inner vessel walls (depicted in red)
progression on MRI at 24 months was also measured. In participants with the largest amount of atherosclerosis progression on MRI (defined as the highest tertile group), we examined whether there was evidence of greater changes in arterial inflammation compared to groups with less atherosclerosis progression (defined as the lowest and middle tertiles). Finally, to examine the impact of short-term structural changes on long-term atherosclerosis progression, we compared changes in MWT (and MWA) on MRI at 6 and 24 months. Analyses were performed using R (version 3.1.4), and a p value of 0.05 was considered the threshold for statistical significance.
Results
Baseline characteristics
Forty-two participants provided complete multi-modal imaging datasets (PET/CT at 0 and 6 months, and MRI at 0 and 24 months). Baseline characteristics of the study population are summarized in Table 1 . The mean age of the population was 62.5 years, and 12 (28.6 %) were women. Thirty-five participants (83.3 %) had a prior history of cardiovascular disease, 14 (33.3 %) were diabetic, 30 (71.4 %) had a history of hypertension and 4 (9.5 %) were smokers. Compared to individuals in dal-PLAQUE who did not provide complete multi-modality data, participants included in this analysis had a lower mean body mass index (BMI) and systolic blood pressure. Also, the baseline FDG target-to-background ratio on PET and the baseline MWT and MWA on MRI were lower in included participants.
Atherosclerosis progression in participants with or without increased arterial inflammation
Eighteen participants (42.8 %) manifested an increase in arterial inflammation measured by PET/CT between baseline and 6 months. Structural atherosclerosis progression measured by percent changes in MWT and MWA on MRI over 24 months are summarized in Table 2 . In participants with an early increase in arterial inflammation (baseline to 6 months), structural atherosclerosis progression was also seen at 2 years. Conversely, in participants with no increased arterial inflammation at 6 months, no significant atherosclerosis progression was observed.
In the univariate linear regression analysis, evidence of increased arterial inflammation at 6 months was associated with a significantly greater change in both MWT and MWA on MRI at 24 months (Table 3 and Fig. 2a ). In participants with increased arterial inflammation on PET over 6 months, the increase in MWT over 24 months was approximately Table 3 and Fig. 2b ). These differences remained significant after adjusting for age, gender and treatment allocation, and for additional clinical, biochemical or imaging variables significantly associated with c h a n g e s i n M W T o n u n i v a r i a t e a n a l y s e s ( s e e Supplementary Table 1) . Results also remained significant after adjusting for structural atherosclerosis measurements obtained at 6 months (i.e. mean wall area on MRI; p = 0.04).
On the other hand, baseline FDG uptake was not significantly associated with percentage change in MWA over 24 months either on univariate analysis (β = −21.01 [SE 11.10], p = 0.07) or after adjusting for demographic variables and treatment allocation (β = −22.9 [SE 13.6], p = 0.10). Furthermore, using covariate adjustments specified in dal-PLAQUE, we evaluated the effect of dalcetrapib on arterial inflammation (carotid atherosclerosis) [6] ; compared to placebo, treatment with dalcetrapib did not significantly reduce carotid inflammation over 6 months (−5.1 % [SE 4.1] change in TBR, p = 0.22). It should be noted, however, that while the findings are consistent with the nonsignificant trend seen in the parent study, this sub-study analysis had limited power to assess the treatment effect.
In sensitivity analyses, we evaluated the association between increased arterial inflammation at 6 months and absolute changes in MWT and MWA at 24 months. The results, which are summarized in Supplementary Table 2, were consistent with our primary observations. Both associations trended towards significance in univariate analyses, and were statistically significant after adjusting for other significant predictors (derived from the primary analysis). Finally, we observed that increased arterial inflammation was also associated with short-term atherosclerosis progression (also measured at 6 months) (Supplementary Table 3 ).
Changes in inflammatory biomarkers and atherosclerosis progression by MRI
Over 24 months, no significant positive associations were observed between changes in inflammatory biomarkers and changes in either MWT or MWA (Supplementary Table 4 ). There was a small inverse association between changes in vascular cell adhesion molecules (VCAM) and both MWT and MWA. A trend towards a significant inverse association was also observed with changes in intercellular adhesion Progression of atherosclerosis at 6 months compared to 24 months measured by MRI Thirteen of 35 participants (35.4 %) had evidence of increasing wall thickness on MRI at 6 months. Evidence of increasing MWT at 6 months was also associated with a greater rate of atherosclerosis progression at 24 months (see Supplementary Table 5 ). Change in MWT at 6 months as a continuous variable was highly correlated with change in MWT at 24 months (Pearson's correlation = 0.64, p < 0.001).
Results using MWA were consistent with those of MWT (see Supplementary Table 5 ).
Discussion
In this sub-study of dal-PLAQUE, we found that short-term changes in arterial inflammation predicted long-term structural atherosclerosis progression. Participants with evidence of increased carotid inflammation measured by FDG-PET over 6 months had greater progression in carotid artery MWT and MWA on MRI at 2 years. Also, in those without evidence of increased arterial inflammation, no significant atherosclerosis progression was observed. Prior histologic, cross-sectional studies of carotid arterial imaging have shown that arterial inflammation measured by FDG-PET closely correlates with macrophage infiltration within the atheroma [10] . Furthermore, carotid inflammation measured by FDG-PET has been shown to precede the development of calcification within the index artery measured by computed tomography [11] . However, while these cross-sectional examinations of arterial inflammation have increased our Fig. 2 Percentage change in carotid (a) mean wall thickness and (b) mean wall area at 24 months in participants with or without evidence of increased arterial inflammation at 6 months understanding of how arterial inflammation relates to both plaque activity and the progression of atherosclerosis, studies had yet to determine how changes in arterial inflammatory activity affect the progression of atherosclerosis.
Our study expands upon current knowledge and provides two important pathophysiologic findings. First, changes in vascular inflammation observed over a short period appear to have both short-and long-term consequences on atherosclerosis progression. Second, in those without evidence of increased inflammation, there were no significant changes in MWT or MWA observed, suggesting that atherosclerosis progression can be substantially mitigated by reducing inflammation. This is also supported by our observations that changes in arterial inflammation were significantly higher in participants with the highest rates of atherosclerosis progression on MRI when compared to groups with evidence of less atherosclerosis progression. The critical threshold delineating those with or without increased inflammation may be of added Fig. 3 Changes in arterial inflammation in groups with the greatest amount of atherosclerosis progression compared to less progression measured by (a) mean wall thickness and (b) mean wall area importance, as we observed stronger associations when participants were dichotomized into these groups than when examining the change in arterial inflammation as a continuous measure (Supplementary Appendix, section 1) .
Previous studies have shown that markers of systemic inflammation (e.g. CRP) also strongly predict plaque progression and cardiovascular events [12] . Interestingly, in our exploratory analyses, we did not observe that changes in inflammatory biomarkers positively corresponded to atherosclerosis progression over the same period. These findings suggest that directly measuring inflammatory changes at the local, vascular level have greater significance for identifying atherosclerosis progression compared to more general inflammatory biomarkers. However, whether this observation is generalizable to larger populations, and how this relates to clinical outcomes, requires further study.
We did not observe an association between baseline FDG arterial uptake on PET and subsequent atherosclerosis progression, a finding that at first look may appear to conflict with prior studies [11] . However, it is important to note that the current study included a pharmacologic intervention (dalcetrapib), which was initiated after baseline imaging; thus the relationship between baseline imaging values and subsequent changes may be significantly confounded by dalcetrapib use. Therefore, comparisons between baseline arterial inflammatory measures and atherosclerosis progression should be interpreted with caution, and do not suggest that cross-sectional PET measures of inflammation are not valuable. Indeed, in individuals who are not enrolled in interventional studies, the baseline arterial signal is associated with both future plaque progression and future clinical events [13] . In 518 patients without a history of active cancer or CVD, we observed that baseline arterial FDG activity strongly predicted future adverse cardiovascular events at a mean follow-up of 4.2 years, and provided additional predictive value above clinical factors [13] . Similarly, in a study of 64 patients with significant symptomatic carotid stenosis who underwent PET imaging, Marnane et al. observed a significant association between carotid arterial inflammation and recurrent ipsilateral stroke [14] . Our findings provide additional insight into these clinical observations, suggesting that atherosclerosis development is also related in part to the consequences of persistent inflammation.
The results of our study further support the use of FDG-PET as a non-invasive imaging modality to predict the clinical impact of novel therapeutic agents on future cardiovascular outcomes. For example, using FDG-PET, a dose-dependent reduction in arterial inflammation was observed over a 12-week period in response to the initiation of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy, which is similar to the dose-dependent reductions in cardiovascular outcomes observed in several large clinical trials [4, 15, 16] . Conversely, in the overall dal-PLAQUE study, CETP modulation did not significantly impact changes in arterial inflammation compared to placebo within any of the predefined PET endpoints (though it was nearly significant in post hoc analyses) [4] . Similarly, dalcetrapib was not found to reduce vascular events in clinical outcome trials [6, 17] . Inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) also failed to reduce atherosclerotic inflammation [18] , a finding that is consistent with the lack of clinical efficacy of Lp-PLA2 antagonists [18] [19] [20] . Most recently, P38 MAP kinase antagonists were found to be ineffective in reducing any of the pre-defined PET endpoints, and have similarly been found to be ineffective in reducing clinical events [21] [22] [23] . Thus, for all classes of drugs for which there is PET imaging and clinical endpoint trial data, the pre-defined PET findings have been concordant with the clinical endpoint findings.
Finally, we explored whether even earlier changes in FDG-PET uptake could predict atherosclerosis progression, and although we found that 3-month changes in arterial inflammation correlated well with 6-month changes in the inflammatory signal, 3-month changes themselves were not predictive of atherosclerosis progression. Ultimately, determining the optimal period for evaluating changes in arterial FDG uptake in order to determine the efficacy of novel therapeutic agents will depend on several factors, including the pharmacological properties of the treatments under investigation.
As anticipated, we also observed that increasing WMT and WMA measured by MRI over 6 months was associated with a higher rate of atherosclerosis progression over 24 months. The consequences of these short-term structural changes to the arterial wall are complementary to our PET findings, and it is likely that these processes are interrelated, with biologically active atherosclerotic lesions also demonstrating early structural changes that predict long-term atherosclerosis progression. Given their low cost and highly favorable benefit-to-risk profiles, current cardiovascular pharmacologic therapies are widely given to patients with established CVD or at high risk for CV events [24, 25] . However, as the development of pharmacologic therapies continues, there may be greater justification for measuring arterial inflammation with PET [18] [19] [20] . Anti-inflammatory strategies for reducing CVD risk are currently being evaluated using both PET/CT imaging and clinical endpoint assessments (including colchicine, methotrexate and interleukin-1 inhibition) [26] . If these are shown to improve both arterial inflammation and clinical outcomes, such studies would provide additional data to support the hypothesis that targeting arterial inflammation per se is clinically beneficial, and would move future phase 1 studies of pharmacologic agents that target inflammation to phase 3 clinical endpoint trials with greater confidence based on FDG-PET results. Also, it is possible that imaging of arterial inflammation could one day be employed to identify those patients most likely to benefit from novel anti-inflammatory drugs (particularly expensive drugs and/or those with substantial side effects). This personalized approach to CVD management would be similar to strategies currently used in oncology, where FDG-PET imaging is used for cancer staging as well as post-induction re-staging of disease burden to guide further management decisions [27] [28] [29] .
The main strength of our paper is that all PET and MRI studies were performed in the context of a clinical trial, where imaging techniques were standardized across sites and results were centrally interpreted. This significantly reduces the risk of bias related to variability in imaging procedures. However, some limitations also warrant consideration. First, our primary outcome measures of MRI MWT and MWA represent noninvasive surrogate markers of atherosclerosis development, since more invasive approaches were not employed in dal-PLAQUE. However, findings of atherosclerosis on MRI have been shown to correlate well with observations of plaque burden by histology or other prognostic imaging modalities. The PET measurement of arterial inflammation can also be influenced by technical factors (e.g. tracer circulation time). To limit this source of bias, standardized protocols for PET image acquisition were applied across the study population. For our analysis, serial PET and MRI images were available in approximately one-third of the participants randomized in dal-PLAQUE. Larger studies are needed to replicate these observations and demonstrate their generalizability to broader patient populations.
In conclusion, our observations demonstrate not only that FDG-PET/CT can quantify the short-lived atherosclerotic inflammatory process, but that identifying these changes is of value in predicting long-term atherosclerosis progression. These findings support the current use of FDG-PET in drug efficacy assessment trials, and its potential use to direct future treatment strategies for targeting inflammatory pathways that inhibit atherosclerosis development.
